drugset
Drugs / VEGFR1-A2-770
last change May 2009 re-read 3 minutes ago

VEGFR1-A2-770

Peptide

Developed for
malignant pancreatic neoplasm
Investigated by
Human Genome Center, Institute of Medical Science, University of Tokyo · Tokyo University

Trials 1

today NCT00683085 · Ph 1/2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00683085 May 2008 → May 2009 malignant pancreatic neoplasm Tokyo University Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as VEGFR1-A2-770 “VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses)” NCT00683085 ↗
Modality Peptide “VEGFR1-derived HLA-A\*02:01-restricted peptide” NCT00683085 ↗
Route Subcutaneous “will be subcutaneously injected” NCT00683085 ↗